Biosimilar Market Report: Trends, Forecast and Competitive Analysis
Get it in 2 to 4 weeks by ordering today
The future of the global biosimilar market looks promising with opportunities in oncology, chronic diseases, blood disorders, and autoimmune diseases. The global biosimilar market is expected to grow with a CAGR of 30%-32% from 2020 to 2025. The major drivers for this market are increasing prevalence of chronic diseases, rising demand for biosimilar drugs, and increase in sedentary lifestyle.
A total of XX figures / charts and XX tables are provided in this more than 150-page report to help in your business decisions. Sample figures with some insights are shown below. To learn the scope, benefits, companies researched, and other details of the global biosimilar market report, please download the report brochure.
biosimilar market
The study includes trends and forecast for the global biosimilar market by product, technology, application, and region as follows:
By Product [Value ($ Million) shipment analysis for 2014 – 2025]:
InsulinMonoclonal AntibodiesRecombinant Human Growth Hormone (rhGH)Granulocyte Colony-Stimulating FactorInterferonErythropoietinEtanerceptFollitropinGlucagonCalcitoninTeriparatideEnoxaparin Sodium
By Technology [Value ($ Million) shipment analysis for 2014 – 2025]:
Recombinant DNA TechnologyMonoclonal Antibodies Technology
By Application [Value ($ Million) shipment analysis for 2014 – 2025]:
OncologyChronic DiseasesBlood DisordersAutoimmune Diseases
By Region [Value ($ Million) shipment analysis for 2014 – 2025]:
North AmericaUnited StatesCanada MexicoEuropeUnited KingdomGermanyFranceAsia PacificChinaIndiaJapanThe Rest of the World Brazil
Some of the biosimilar companies profiled in this report include Pfizer, Novartis, Biocon, Fresenius Kabi, Boehringer Ingelheim, Mylan, Eli Lilly Teva Pharmaceutical, Dr. Reddy's Laboratories, and Amgen.
Lucintel forecasts that monoclonal antibodies will remain the largest product segment over the forecast period due to increasing prevalence of chronic diseases, such as cancer, and a rising number of new product developments in the segment.
Within this market, oncology will remain the largest segment by application over the forecast period due to increasing cases of cancer, recent approvals of biosimilars for treatment of cancer, and new product launches in the field of oncology.
Europe will remain the largest region over the forecast period due to increasing geriatric population, presence of a well-defined regulatory framework by governments for biosimilars, and increasing prevalance of chronic diseases in the region.
Features of the Global Biosimilar Market
Market Size Estimates: Global biosimilar market size estimation in terms of value ($M) shipment.Trend and Forecast Analysis: Market trends (2014-2019) and forecast (2020-2025) by various segments.Segmentation Analysis: Global biosimilar market size by various segments, such as product, technology, and application, in terms of value.Regional Analysis: Global biosimilar market breakdown by North America, Europe, Asia Pacific, and Rest of the World.Growth Opportunities: Analysis of growth opportunities in different products, technologies, applications, and regions for the global biosimilar market.Strategic Analysis: This includes M&A, new product development, and competitive landscape of the global biosimilar market.Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
This report answers following key questions
Q.1 What are some of the most promising potential, high-growth opportunities for the global biosimilar market by product (insulin, monoclonal antibodies, recombinant human growth hormone (rhGH), granulocyte colony-stimulating factor, interferon, erythropoietin, etanercept, follitropin, glucagon, calcitonin, teriparatide, and enoxaparin sodium), technology (recombinant DNA technology and monoclonal antibodies technology), application (oncology, chronic diseases, blood disorders, and autoimmune diseases), and region (North America, Europe, Asia Pacific, and Rest of the World)?
Q.2 Which segments will grow at a faster pace and why?
Q.3 Which region will grow at a faster pace and why?
Q.4 What are the key factors affecting market dynamics? What are the drivers and challenges of the global biosimilar market?
Q.5 What are the business risks and threats to the global biosimilar market?
Q.6 What are the emerging trends in this biosimilar market and the reasons behind them?
Q.7 What are some changing demands of customers in this biosimilar market?
Q.8 What are the new developments in this biosimilar market? Which companies are leading these developments?
Q.9 Who are the major players in this biosimilar market? What strategic initiatives are being implemented by key players for business growth?
Q.10 What are some of the competitive products and processes in this biosimilar market, and how big of a threat do they pose for loss of market share via material or product substitution?
Q.11 What M&A activities did take place in the last five years in the global biosimilar market?
Report Scope
Key Features Description
Base Year for Estimation 2019
Trend Period
(Actual Estimates) 2014-2019
Forecast Period 2020-2025
Pages More than 150
Market Representation / Units Revenue in US $ Million
Report Coverage Market Trends & Forecast, Competitor Analysis, New Product Development, Company Expansion, Merger, Acquisitions & Joint Venture, and Company Profiling
Market Segments Product (Insulin, Monoclonal Antibodies, Recombinant Human Growth Hormone (rhGH), Granulocyte Colony-Stimulating Factor, Interferon, Erythropoietin, Etanercept, Follitropin, Glucagon, Calcitonin, Teriparatide, and Enoxaparin Sodium), Technology (Recombinant DNA Technology and Monoclonal Antibodies Technology, and Application (Oncology, Chronic Diseases, Blood Disorders, and Autoimmune Diseases)
Regional Scope North America (USA, Mexico, and Canada), Europe (United Kingdom, Germany, and France), Asia Pacific (China, India, and Japan), and ROW (Brazil)
Customization 10% Customization without Any Additional Cost
The future of the global biosimilar market looks promising with opportunities in oncology, chronic diseases, blood disorders, and autoimmune diseases. The global biosimilar market is expected to grow with a CAGR of 30%-32% from 2020 to 2025. The major drivers for this market are increasing prevalence of chronic diseases, rising demand for biosimilar drugs, and increase in sedentary lifestyle.
A total of XX figures / charts and XX tables are provided in this more than 150-page report to help in your business decisions. Sample figures with some insights are shown below. To learn the scope, benefits, companies researched, and other details of the global biosimilar market report, please download the report brochure.
biosimilar market
The study includes trends and forecast for the global biosimilar market by product, technology, application, and region as follows:
By Product [Value ($ Million) shipment analysis for 2014 – 2025]:
InsulinMonoclonal AntibodiesRecombinant Human Growth Hormone (rhGH)Granulocyte Colony-Stimulating FactorInterferonErythropoietinEtanerceptFollitropinGlucagonCalcitoninTeriparatideEnoxaparin Sodium
By Technology [Value ($ Million) shipment analysis for 2014 – 2025]:
Recombinant DNA TechnologyMonoclonal Antibodies Technology
By Application [Value ($ Million) shipment analysis for 2014 – 2025]:
OncologyChronic DiseasesBlood DisordersAutoimmune Diseases
By Region [Value ($ Million) shipment analysis for 2014 – 2025]:
North AmericaUnited StatesCanada MexicoEuropeUnited KingdomGermanyFranceAsia PacificChinaIndiaJapanThe Rest of the World Brazil
Some of the biosimilar companies profiled in this report include Pfizer, Novartis, Biocon, Fresenius Kabi, Boehringer Ingelheim, Mylan, Eli Lilly Teva Pharmaceutical, Dr. Reddy's Laboratories, and Amgen.
Lucintel forecasts that monoclonal antibodies will remain the largest product segment over the forecast period due to increasing prevalence of chronic diseases, such as cancer, and a rising number of new product developments in the segment.
Within this market, oncology will remain the largest segment by application over the forecast period due to increasing cases of cancer, recent approvals of biosimilars for treatment of cancer, and new product launches in the field of oncology.
Europe will remain the largest region over the forecast period due to increasing geriatric population, presence of a well-defined regulatory framework by governments for biosimilars, and increasing prevalance of chronic diseases in the region.
Features of the Global Biosimilar Market
Market Size Estimates: Global biosimilar market size estimation in terms of value ($M) shipment.Trend and Forecast Analysis: Market trends (2014-2019) and forecast (2020-2025) by various segments.Segmentation Analysis: Global biosimilar market size by various segments, such as product, technology, and application, in terms of value.Regional Analysis: Global biosimilar market breakdown by North America, Europe, Asia Pacific, and Rest of the World.Growth Opportunities: Analysis of growth opportunities in different products, technologies, applications, and regions for the global biosimilar market.Strategic Analysis: This includes M&A, new product development, and competitive landscape of the global biosimilar market.Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
This report answers following key questions
Q.1 What are some of the most promising potential, high-growth opportunities for the global biosimilar market by product (insulin, monoclonal antibodies, recombinant human growth hormone (rhGH), granulocyte colony-stimulating factor, interferon, erythropoietin, etanercept, follitropin, glucagon, calcitonin, teriparatide, and enoxaparin sodium), technology (recombinant DNA technology and monoclonal antibodies technology), application (oncology, chronic diseases, blood disorders, and autoimmune diseases), and region (North America, Europe, Asia Pacific, and Rest of the World)?
Q.2 Which segments will grow at a faster pace and why?
Q.3 Which region will grow at a faster pace and why?
Q.4 What are the key factors affecting market dynamics? What are the drivers and challenges of the global biosimilar market?
Q.5 What are the business risks and threats to the global biosimilar market?
Q.6 What are the emerging trends in this biosimilar market and the reasons behind them?
Q.7 What are some changing demands of customers in this biosimilar market?
Q.8 What are the new developments in this biosimilar market? Which companies are leading these developments?
Q.9 Who are the major players in this biosimilar market? What strategic initiatives are being implemented by key players for business growth?
Q.10 What are some of the competitive products and processes in this biosimilar market, and how big of a threat do they pose for loss of market share via material or product substitution?
Q.11 What M&A activities did take place in the last five years in the global biosimilar market?
Report Scope
Key Features Description
Base Year for Estimation 2019
Trend Period
(Actual Estimates) 2014-2019
Forecast Period 2020-2025
Pages More than 150
Market Representation / Units Revenue in US $ Million
Report Coverage Market Trends & Forecast, Competitor Analysis, New Product Development, Company Expansion, Merger, Acquisitions & Joint Venture, and Company Profiling
Market Segments Product (Insulin, Monoclonal Antibodies, Recombinant Human Growth Hormone (rhGH), Granulocyte Colony-Stimulating Factor, Interferon, Erythropoietin, Etanercept, Follitropin, Glucagon, Calcitonin, Teriparatide, and Enoxaparin Sodium), Technology (Recombinant DNA Technology and Monoclonal Antibodies Technology, and Application (Oncology, Chronic Diseases, Blood Disorders, and Autoimmune Diseases)
Regional Scope North America (USA, Mexico, and Canada), Europe (United Kingdom, Germany, and France), Asia Pacific (China, India, and Japan), and ROW (Brazil)
Customization 10% Customization without Any Additional Cost
1. EXECUTIVE SUMMARY
2. MARKET BACKGROUND AND CLASSIFICATIONS
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges
3. MARKET TRENDS AND FORECAST ANALYSIS FROM 2014 T 2025
3.1: Macroeconomic Trends and Forecast
3.2: Global Biosimilar Market Trends and Forecast
3.3: Global Biosimilar Market by Product
3.3.1: Insulin
3.3.2: Monoclonal Antibodies
3.3.3: Recombinant Human Growth Hormone (rhGH)
3.3.4: Granulocyte Colony-Stimulating Factor
3.3.5: Interferon
3.3.6: Erythropoietin
3.3.7: Etanercept
3.3.8: Follitropin
3.3.9: Glucagon
3.3.10: Calcitonin
3.3.11: Teriparatide
3.3.12: Enoxaparin Sodium
3.4: Global Biosimilar Market by Technology
3.4.1: Recombinant DNA Technology
3.4.2: Monoclonal Antibodies Technology
3.5: Global Biosimilar Market by Application
3.5.1: Oncology
3.5.2: Chronic Diseases
3.5.3: Blood Disorders
3.5.4: Autoimmune Diseases
4. MARKET TRENDS AND FORECAST ANALYSIS BY REGION
4.1: Global Biosimilar Market by Region
4.2: North American Biosimilar Market
4.2.1: Market by Product: Insulin, Monoclonal Antibodies, Recombinant Human Growth Hormone (rhGH), Granulocyte Colony-stimulating Factor, Interferon, Erythropoietin, Etanercept, Follitropin, Glucagon, Calcitonin, Teriparatide, and Enoxaparin Sodium
4.2.2: Market by Technology: Recombinant DNA Technology and Monoclonal Antibodies Technology
4.2.3: Market by Application: Oncology, Chronic Disease, Blood Disorder, and Autoimmune Disease
4.2.4: The United States Biosimilar Market
4.2.5: The Canadian Biosimilar Market
4.2.6: The Mexican Biosimilar Market
4.3: European Biosimilar Market
4.3.1: Market by Product: Insulin, Monoclonal Antibodies, Recombinant Human Growth Hormone (rhGH), Granulocyte Colony-stimulating Factor, Interferon, Erythropoietin, Etanercept, Follitropin, Glucagon, Calcitonin, Teriparatide, and Enoxaparin Sodium
4.3.2: Market by Technology: Recombinant DNA Technology and Monoclonal Antibodies Technology
4.3.3: Market by Application: Oncology, Chronic Disease, Blood Disorder, and Autoimmune Disease
4.3.4: The Biosimilar Market of the United Kingdom
4.3.5: The German Biosimilar Market
4.3.6: The French Biosimilar Market
4.4: APAC Biosimilar Market
4.4.1: Market by Product: Insulin, Monoclonal Antibodies, Recombinant Human Growth Hormone (rhGH), Granulocyte Colony-stimulating Factor, Interferon, Erythropoietin, Etanercept, Follitropin, Glucagon, Calcitonin, Teriparatide, and Enoxaparin Sodium
4.4.2: Market by Technology: Recombinant DNA Technology and Monoclonal Antibodies Technology
4.4.3: Market by Application: Oncology, Chronic Disease, Blood Disorder, and Autoimmune Disease
4.4.4: The Chinese Biosimilar Market
4.4.5: The Indian Biosimilar Market
4.4.6: The Japanese Biosimilar Market
4.5: ROW Biosimilar Market
4.5.1: Market by Product: Insulin, Monoclonal Antibodies, Recombinant Human Growth Hormone (rhGH), Granulocyte Colony-stimulating Factor, Interferon, Erythropoietin, Etanercept, Follitropin, Glucagon, Calcitonin, Teriparatide, and Enoxaparin Sodium
4.5.2: Market by Technology: Recombinant DNA Technology and Monoclonal Antibodies Technology
4.5.3: Market by Application: Oncology, Chronic Disease, Blood Disorder, and Autoimmune Disease
4.5.5: Brazilian Biosimilar Market
5. COMPETITOR ANALYSIS
5.1: Market Share Analysis
5.2: Product Portfoli Analysis
5.3: Operational Integration
5.4: Geographical Reach
5.5: Porter’s Five Forces Analysis
6. COST STRUCTURE ANALYSIS
6.1: Cost of Goods Sold
6.2: SG&A
6.3: EBITDA Margin
7. GROWTH OPPORTUNITIES AND STRATEGIC ANALYSIS
7.1: Growth Opportunity Analysis
7.1.1: Growth Opportunities for the Global Biosimilar Market by Product
7.1.2: Growth Opportunities for the Global Biosimilar Market by Technology
7.1.3: Growth Opportunities for the Global Biosimilar Market by Application
7.1.4: Growth Opportunities for the Global Biosimilar Market by Region
7.2: Emerging Trends in the Global Biosimilar Market
7.3: Strategic Analysis
7.3.1: New Product Development
7.3.2: Capacity Expansion of the Global Biosimilar Market
7.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Biosimilar Market
7.3.4: Certification and Licensing
8. COMPANY PROFILES OF LEADING PLAYERS
8.1: Pfizer
8.2: Novartis
8.3: Biocon
8.4: Fresenius Kabi AG
8.5: Boehringer Ingelheim
8.6: Mylan
8.7: Eli Lilly
8.8: Teva Pharmaceutical
8.9: Dr. Reddy's Laboratories
8.10: Amgen
2. MARKET BACKGROUND AND CLASSIFICATIONS
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges
3. MARKET TRENDS AND FORECAST ANALYSIS FROM 2014 T 2025
3.1: Macroeconomic Trends and Forecast
3.2: Global Biosimilar Market Trends and Forecast
3.3: Global Biosimilar Market by Product
3.3.1: Insulin
3.3.2: Monoclonal Antibodies
3.3.3: Recombinant Human Growth Hormone (rhGH)
3.3.4: Granulocyte Colony-Stimulating Factor
3.3.5: Interferon
3.3.6: Erythropoietin
3.3.7: Etanercept
3.3.8: Follitropin
3.3.9: Glucagon
3.3.10: Calcitonin
3.3.11: Teriparatide
3.3.12: Enoxaparin Sodium
3.4: Global Biosimilar Market by Technology
3.4.1: Recombinant DNA Technology
3.4.2: Monoclonal Antibodies Technology
3.5: Global Biosimilar Market by Application
3.5.1: Oncology
3.5.2: Chronic Diseases
3.5.3: Blood Disorders
3.5.4: Autoimmune Diseases
4. MARKET TRENDS AND FORECAST ANALYSIS BY REGION
4.1: Global Biosimilar Market by Region
4.2: North American Biosimilar Market
4.2.1: Market by Product: Insulin, Monoclonal Antibodies, Recombinant Human Growth Hormone (rhGH), Granulocyte Colony-stimulating Factor, Interferon, Erythropoietin, Etanercept, Follitropin, Glucagon, Calcitonin, Teriparatide, and Enoxaparin Sodium
4.2.2: Market by Technology: Recombinant DNA Technology and Monoclonal Antibodies Technology
4.2.3: Market by Application: Oncology, Chronic Disease, Blood Disorder, and Autoimmune Disease
4.2.4: The United States Biosimilar Market
4.2.5: The Canadian Biosimilar Market
4.2.6: The Mexican Biosimilar Market
4.3: European Biosimilar Market
4.3.1: Market by Product: Insulin, Monoclonal Antibodies, Recombinant Human Growth Hormone (rhGH), Granulocyte Colony-stimulating Factor, Interferon, Erythropoietin, Etanercept, Follitropin, Glucagon, Calcitonin, Teriparatide, and Enoxaparin Sodium
4.3.2: Market by Technology: Recombinant DNA Technology and Monoclonal Antibodies Technology
4.3.3: Market by Application: Oncology, Chronic Disease, Blood Disorder, and Autoimmune Disease
4.3.4: The Biosimilar Market of the United Kingdom
4.3.5: The German Biosimilar Market
4.3.6: The French Biosimilar Market
4.4: APAC Biosimilar Market
4.4.1: Market by Product: Insulin, Monoclonal Antibodies, Recombinant Human Growth Hormone (rhGH), Granulocyte Colony-stimulating Factor, Interferon, Erythropoietin, Etanercept, Follitropin, Glucagon, Calcitonin, Teriparatide, and Enoxaparin Sodium
4.4.2: Market by Technology: Recombinant DNA Technology and Monoclonal Antibodies Technology
4.4.3: Market by Application: Oncology, Chronic Disease, Blood Disorder, and Autoimmune Disease
4.4.4: The Chinese Biosimilar Market
4.4.5: The Indian Biosimilar Market
4.4.6: The Japanese Biosimilar Market
4.5: ROW Biosimilar Market
4.5.1: Market by Product: Insulin, Monoclonal Antibodies, Recombinant Human Growth Hormone (rhGH), Granulocyte Colony-stimulating Factor, Interferon, Erythropoietin, Etanercept, Follitropin, Glucagon, Calcitonin, Teriparatide, and Enoxaparin Sodium
4.5.2: Market by Technology: Recombinant DNA Technology and Monoclonal Antibodies Technology
4.5.3: Market by Application: Oncology, Chronic Disease, Blood Disorder, and Autoimmune Disease
4.5.5: Brazilian Biosimilar Market
5. COMPETITOR ANALYSIS
5.1: Market Share Analysis
5.2: Product Portfoli Analysis
5.3: Operational Integration
5.4: Geographical Reach
5.5: Porter’s Five Forces Analysis
6. COST STRUCTURE ANALYSIS
6.1: Cost of Goods Sold
6.2: SG&A
6.3: EBITDA Margin
7. GROWTH OPPORTUNITIES AND STRATEGIC ANALYSIS
7.1: Growth Opportunity Analysis
7.1.1: Growth Opportunities for the Global Biosimilar Market by Product
7.1.2: Growth Opportunities for the Global Biosimilar Market by Technology
7.1.3: Growth Opportunities for the Global Biosimilar Market by Application
7.1.4: Growth Opportunities for the Global Biosimilar Market by Region
7.2: Emerging Trends in the Global Biosimilar Market
7.3: Strategic Analysis
7.3.1: New Product Development
7.3.2: Capacity Expansion of the Global Biosimilar Market
7.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Biosimilar Market
7.3.4: Certification and Licensing
8. COMPANY PROFILES OF LEADING PLAYERS
8.1: Pfizer
8.2: Novartis
8.3: Biocon
8.4: Fresenius Kabi AG
8.5: Boehringer Ingelheim
8.6: Mylan
8.7: Eli Lilly
8.8: Teva Pharmaceutical
8.9: Dr. Reddy's Laboratories
8.10: Amgen
